MedTrace Logo

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

NCT06219356 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-08-19

No results posted yet for this study

Summary

Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).

Conditions

Interventions

DRUG

GLB-002

Administered orally according to the assigned treatment schedule.

Sponsors & Collaborators

  • Hangzhou GluBio Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Gang Lu, Ph.D. · Hangzhou GluBio Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-11
Primary Completion
2026-01-31
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06219356 on ClinicalTrials.gov